Comparison · NCT01120028-e7809c46
Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy. Trial comparisons, record NCT01120028-e7809c46. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01120028-e7809c46
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0728 | 0.0517 | 0.101 | wilson | |
| Risk in group 2 | 0.16 | 0.128 | 0.197 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0869 | -0.13 | -0.0441 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.456 | 0.305 | 0.682 | log | |
| Odds ratio, group 1 over group 2 | 0.413 | 0.264 | 0.647 | log | |
| Number needed to treat, for one fewer participant with the outcome on Period 1: Alemtuzumab/Tacrolimus than on Period 1: Basiliximab/Tacrolimus | 11.5 | 7.69 | 22.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Period 1: Alemtuzumab/Tacrolimus | Induction therapy allocation: Alemtuzumab (Campath-1H) and Tacrolimus~Alemtuzumab: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart~Tacrolimus: Target trough level 5-7 ng/mL for 6-months after alemtuzumab. | 31 | 426 | OG000 |
| Group 2 | Period 1: Basiliximab/Tacrolimus | Induction therapy allocation: Basiliximab and Tacrolimus~Basiliximab: 20 mg intravenously, two doses 96 hours apart~Tacrolimus: Target trough level 5-12 ng/mL for 6-months after basiliximab | 68 | 426 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy
- Description
- Occurence of biopsy-proven acute rejection events at 6-months after transplantation during Period 1 (randomization to induction therapy (Campath-1H and Tacrolimus, or Basiliximab and Tacrolimus))
- Time frame
- 6 months post-transplantation
- Population
Source ClinicalTrials.gov
Trial
- Title
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- NCT number
- NCT01120028
- Phases
- PHASE2, PHASE3
- Conditions
- Kidney Transplantation
- Interventions
- Alemtuzumab, Basiliximab, Sirolimus, Tacrolimus
- Lead sponsor
- University of Oxford
- Results first posted
- 2019-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01120028?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01120028-e7809c46